Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Identifying early chemoimmunotherapy failure (ECF) in diffuse large B-cell lymphoma is crucial. This study developed a predictive model for ECF, identifying key clinical and molecular factors to improve patient outcomes.
Area Of Science
- Hematology
- Oncology
- Genetics
Background
- Refractory or relapsed diffuse large B-cell lymphoma (DLBCL) has poor outcomes.
- Early chemoimmunotherapy failure (ECF) within 12 months of diagnosis has a dismal 2-year overall survival (OS) of 24.7%.
Purpose Of The Study
- To identify predictors of ECF in DLBCL patients.
- To develop a predictive model for early recognition of ECF.
- To improve therapeutic strategies and outcomes for chemo-resistant DLBCL patients.
Main Methods
- Retrospective analysis of 2038 newly diagnosed DLBCL patients treated with R-CHOP/RminiCHOP or R-CHOP-based immunochemotherapy.
- Multivariate analysis to identify independent predictors of ECF.
- Development and validation of a nomogram-based ECF prediction model.
Main Results
- ECF patients were associated with elderly age, advanced Ann Arbor stage, elevated LDH, poor performance status, extranodal involvement, double expressor lymphoma (DEL), and non-GCB subtype.
- TP53, FOXO1, and FBXW7 mutations were frequent in ECF.
- Elderly age, advanced stage, elevated LDH, DEL, and TP53 or FOXO1 mutations were independent predictors of ECF.
Conclusions
- A nomogram predicting ECF was established with good predictive power in both Chinese and Western cohorts.
- The ECF prediction model enables early identification of high-risk patients.
- Optimizing therapeutic strategies for early identified ECF patients can improve outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
